NCT00552279 - Immunogenicity and Safety of GlaxoSmithKline Biologicals' Huma Papillomavirus (HPV) Vaccine 580299 in Healthy Females 15 - 25 Years of Age | Biotech Hunter

Enrollment

805

Participants

Timeline

Start Date

November 12, 2007

Primary Completion Date

February 26, 2009

Study Completion Date

July 20, 2009

Conditions

Infections, Papillomavirus

Interventions

BIOLOGICAL

Cervarix TM

Intramuscular administration into the deltoid region of the non-dominant arm according to a 0, 1, 12-month schedule.

BIOLOGICAL

Cervarix TM

Intramuscular administration into the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule.

Trial Locations (16)

20122

GSK Investigational Site, Milan

22102

GSK Investigational Site, Bucharest

25123

GSK Investigational Site, Brescia

26900

GSK Investigational Site, Lodi

90127

GSK Investigational Site, Palermo

97100

GSK Investigational Site, Ragusa

400217

GSK Investigational Site, Cluj-Napoca

550245

GSK Investigational Site, Sibiu

09127

GSK Investigational Site, Cagliari

07100

GSK Investigational Site, Sassari

010507

GSK Investigational Site, Bucharest

077190

GSK Investigational Site, Bucharest

Unknown

GSK Investigational Site, Sibiu

026 01

GSK Investigational Site, Dolný Kubín

018 51

GSK Investigational Site, Nová Dubnica

911 01

GSK Investigational Site, Trenčín